alirocumab vs simvastatin
Side-by-side comparison of alirocumab and simvastatin Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
Zocor
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
Ezetimibe and simvastatin is a combination medicine that helps lower bad cholesterol (LDL-C) in your blood. It can also reduce the risk of heart problems like heart attack and stroke.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
This medicine is used to lower high LDL cholesterol. It is used along with a healthy diet. It can help adults and children 10 years and older who have certain inherited cholesterol problems. It can also lower the risk of heart problems in adults with heart disease, blood vessel disease, or diabetes.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Ezetimibe and simvastatin works in two ways to lower cholesterol. Ezetimibe stops your body from absorbing cholesterol from food. Simvastatin blocks a substance your body needs to make cholesterol.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Headache
- • Upper respiratory tract infection
- • Muscle pain
- • Diarrhea
- Muscle pain 1,655
- Missed dose 1,364
- Pain at injection site 1,278
- Muscle spasms 1,162
- Joint pain 1,053
- Tiredness 13,573
- Feeling sick to your stomach 12,944
- Shortness of breath 12,429
- Diarrhea 11,813
- Medicine not working 11,356
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
This medicine can cause muscle problems, including rhabdomyolysis, which can lead to kidney damage and death. The risk is higher if you are over 65, have kidney problems, or take certain other medicines. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. This medicine can also cause liver problems. Your doctor may do blood tests to check your liver before and during treatment.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
Do not take this medicine if you are pregnant. It can harm your unborn baby. Talk to your doctor if you are breastfeeding or plan to breastfeed, as it is not recommended during treatment with this medicine.
Also Compare — Nearby Drugs
Compare alirocumab with
Compare simvastatin with
How to Read This alirocumab vs simvastatin Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while simvastatin sits within the HMG-CoA Reductase Inhibitor (Statin) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while simvastatin has 62,115. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between alirocumab and simvastatin — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.